Despite setbacks, Sarepta’s gene therapy pipeline and market leadership in DMD present a high-risk, high-reward setup. Read more on SRPT stock here.

In the full year 2024, Sarepta recorded a net income of $235.2 million. Sarepta ended Q1 2025 with $647.5 million in cash, cash equivalents, and investments. Conclusion ...

Sarepta’s financial outlook reflects the potential of its innovative therapies. Analysts project substantial revenue growth, with estimates suggesting an increase from $933 million in 2022 to ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Sarepta Therapeutics is down 83.1% since the beginning of the year, and at $20.91 per share, it is trading 87.2% below its 52-week high of $163.85 from June 2024.

Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The announcement of a safety update for ELEVIDYS, concerning severe side effects and ...

Sarepta Therapeutics shares sank to their lowest level in nine years Monday after a second patient taking its Elevidys drug died. The patient was being treated for Duchenne muscular dystrophy, and ...

Pharma Sarepta reports 2nd death after DMD gene therapy Elevidys, stops dosing in half of patients By Angus Liu Jun 16, 2025 10:58am ...

Sarepta will share the panel’s recommendations with the U.S. Food & Drug Administration (FDA), and implementation of any new regimen will be subject to FDA guidance and allowance. In the ...

Investor Contact: Ian Estepan 617-274-4052 [email protected] Media Contacts: Tracy Sorrentino 617-301-8566 [email protected] Kara Hoeger 617-710-3898 [email protected] ...

Analyst cuts Sarepta’s rating due to uncertain safety and future revenue potential. From tariffs to inflation, macro risks are rising—Matt Maley reveals how he’s trading it all, live this ...